Volition Signs First Human Out Licensing Deal

Core Insights - VolitionRx Limited has signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome (APS) with Werfen's Immunoassay Technology Center, a leader in specialized diagnostics [1][2][3] Company Overview - VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics and developing cost-effective blood tests for early detection and monitoring of diseases [13][14] - Werfen is a family-owned company founded in 1966, specializing in diagnostics in areas such as Hemostasis and Autoimmunity, with worldwide sales of €2.2 billion in 2024 [12] Agreement Details - The agreement allows Werfen to access Volition's proprietary Nu.Q® H3.1 NETs assay to investigate its clinical utility in managing APS patients [3][4] - Werfen has the option to negotiate exclusive commercial rights for launching the product [3] Clinical Implications - APS affects approximately four million people globally and is associated with increased risks of blood clots and complications such as stroke and heart attack [5][10] - The Nu.Q® NETs test is being investigated as a potential biomarker for APS, which could improve diagnostic information and patient monitoring [7][8] Technological Advancements - Early results from the Nu.Q® NETs assay on Werfen's ACL AcuStar® platform show promising detection levels in APS patients [4] - The collaboration aims to validate the clinical utility of the Nu.Q® test as a risk indicator for thrombosis in APS patients [4][6]